BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12127685)

  • 1. Genetic parameters of neuroblastomas.
    Westermann F; Schwab M
    Cancer Lett; 2002 Oct; 184(2):127-47. PubMed ID: 12127685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma.
    Spitz R; Hero B; Ernestus K; Berthold F
    Med Pediatr Oncol; 2003 Jul; 41(1):30-5. PubMed ID: 12764740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing histopathological classification with MYCN, 1p36 and 17q status detected by fluorescence in situ hybridisation from 14 untreated primary neuroblastomas in Singapore.
    Yong MH; Hwang WS; Knight LA; Fung W; Chan MY; Seow WT; Chui CH
    Singapore Med J; 2009 Nov; 50(11):1090-4. PubMed ID: 19960166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human neuroblastoma: from basic science to clinical debut of cellular oncogenes.
    Schwab M
    Naturwissenschaften; 1999 Feb; 86(2):71-8. PubMed ID: 10084150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.
    Bown N; Cotterill S; Lastowska M; O'Neill S; Pearson AD; Plantaz D; Meddeb M; Danglot G; Brinkschmidt C; Christiansen H; Laureys G; Speleman F; Nicholson J; Bernheim A; Betts DR; Vandesompele J; Van Roy N
    N Engl J Med; 1999 Jun; 340(25):1954-61. PubMed ID: 10379019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative genomic hybridization (CGH) analysis of stage 4 neuroblastoma reveals high frequency of 11q deletion in tumors lacking MYCN amplification.
    Plantaz D; Vandesompele J; Van Roy N; Lastowska M; Bown N; Combaret V; Favrot MC; Delattre O; Michon J; Bénard J; Hartmann O; Nicholson JC; Ross FM; Brinkschmidt C; Laureys G; Caron H; Matthay KK; Feuerstein BG; Speleman F
    Int J Cancer; 2001 Mar; 91(5):680-6. PubMed ID: 11267980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deletion of chromosome 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphisms.
    Martinsson T; Sjöberg RM; Hedborg F; Kogner P
    Cancer Res; 1995 Dec; 55(23):5681-6. PubMed ID: 7585654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular cytogenetic characterization of two non-MYCN amplified neuroblastoma cell lines with complex t(11;17).
    McConville CM; Dyer S; Rees SA; Luttikhuis ME; McMullan DJ; Vickers SJ; Ramani P; Redfern D; Morland BJ
    Cancer Genet Cytogenet; 2001 Oct; 130(2):133-40. PubMed ID: 11675134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative genomic hybridization analysis of human neuroblastomas: detection of distal 1p deletions and further molecular genetic characterization of neuroblastoma cell lines.
    Van Roy N; Jauch A; Van Gele M; Laureys G; Versteeg R; De Paepe A; Cremer T; Speleman F
    Cancer Genet Cytogenet; 1997 Sep; 97(2):135-42. PubMed ID: 9283597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluorescence in situ hybridization analysis of chromosome 1p36 deletions in human MYCN amplified neuroblastoma.
    Komuro H; Valentine MB; Rowe ST; Kidd VJ; Makino S; Brodeur GM; Cohn SL; Look AT
    J Pediatr Surg; 1998 Nov; 33(11):1695-8. PubMed ID: 9856898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroblastoma--clinical applications of molecular parameters.
    Brodeur GM
    Brain Pathol; 1990 Sep; 1(1):47-54. PubMed ID: 1669693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chromosomes that show partial loss or gain in near-diploid tumors coincide with chromosomes that show whole loss or gain in near-triploid tumors: evidence suggesting the involvement of the same genes in the tumorigenesis of high- and low-risk neuroblastomas.
    Tomioka N; Kobayashi H; Kageyama H; Ohira M; Nakamura Y; Sasaki F; Todo S; Nakagawara A; Kaneko Y
    Genes Chromosomes Cancer; 2003 Feb; 36(2):139-50. PubMed ID: 12508242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma.
    Caron H; van Sluis P; de Kraker J; Bökkerink J; Egeler M; Laureys G; Slater R; Westerveld A; Voûte PA; Versteeg R
    N Engl J Med; 1996 Jan; 334(4):225-30. PubMed ID: 8531999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas.
    Guo C; White PS; Hogarty MD; Brodeur GM; Gerbing R; Stram DO; Maris JM
    Med Pediatr Oncol; 2000 Dec; 35(6):544-6. PubMed ID: 11107113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma.
    Ambros IM; Zellner A; Roald B; Amann G; Ladenstein R; Printz D; Gadner H; Ambros PF
    N Engl J Med; 1996 Jun; 334(23):1505-11. PubMed ID: 8618605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distal chromosome 17 gains in neuroblastomas detected by comparative genomic hybridization (CGH) are associated with a poor clinical outcome.
    Brinkschmidt C; Christiansen H; Terpe HJ; Simon R; Lampert F; Boecker W; Dockhorn-Dworniczak B
    Med Pediatr Oncol; 2001 Jan; 36(1):11-3. PubMed ID: 11464859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYCN amplification and 17q in neuroblastoma: evidence for structural association.
    O'Neill S; Ekstrom L; Lastowska M; Roberts P; Brodeur GM; Kees UR; Schwab M; Bown N
    Genes Chromosomes Cancer; 2001 Jan; 30(1):87-90. PubMed ID: 11107180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitive and reliable detection of genomic imbalances in human neuroblastomas using comparative genomic hybridisation analysis.
    Van Gele M; Van Roy N; Jauch A; Laureys G; Benoit Y; Schelfhout V; De Potter CR; Brock P; Uyttebroeck A; Sciot R; Schuuring E; Versteeg R; Speleman F
    Eur J Cancer; 1997 Oct; 33(12):1979-82. PubMed ID: 9516837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification.
    Fong CT; Dracopoli NC; White PS; Merrill PT; Griffith RC; Housman DE; Brodeur GM
    Proc Natl Acad Sci U S A; 1989 May; 86(10):3753-7. PubMed ID: 2566996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disomy 1 with terminal 1p deletion is frequent in mass-screening-negative/late-presenting neuroblastomas in young children, but not in mass-screening-positive neuroblastomas in infants.
    Kaneko Y; Kobayashi H; Maseki N; Nakagawara A; Sakurai M
    Int J Cancer; 1999 Jan; 80(1):54-9. PubMed ID: 9935230
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.